Selected research
Industry Research
Cannabinoid-based Antitumor Drug Industry Research Report 2026
Market perspective
The global Cannabinoid-based Antitumor Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Cannabinoid-based Antitumor Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Cannabinoid-based Antitumor Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Cannabinoid-based Antitumor Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Cannabinoid-based Antitumor Drug include Cannabics Inc., GW Pharmaceuticals, Jay Pharma, Medicanja Ltd, Tikun Olam and Valeant Pharmaceuticals, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Cannabinoid-based Antitumor Drug market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Cannabinoid-based Antitumor Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cannabinoid-based Antitumor Drug Market by Company
Cannabics Inc.
GW Pharmaceuticals
Jay Pharma
Medicanja Ltd
Tikun Olam
Valeant Pharmaceuticals
Cannabinoid-based Antitumor Drug Segment by Type
Chewing Medicine
Lozenge
Other
Cannabinoid-based Antitumor Drug Segment by Application
Clinics
Hospitals
Others
Cannabinoid-based Antitumor Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cannabinoid-based Antitumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cannabinoid-based Antitumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cannabinoid-based Antitumor Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Cannabinoid-based Antitumor Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Chewing Medicine
- Lozenge
- Other
Applications
- Clinics
- Hospitals
- Others
Companies covered
- Cannabics Inc.
- GW Pharmaceuticals
- Jay Pharma
- Medicanja Ltd
- Tikun Olam
- Valeant Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Cannabinoid-based Antitumor Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Chewing Medicine
- 2.2.3 Lozenge
- 2.2.4 Other
- 2.3 Cannabinoid-based Antitumor Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Clinics
- 2.3.3 Hospitals
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Cannabinoid-based Antitumor Drug Breakdown Data by Type
- 3.1 Global Cannabinoid-based Antitumor Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Cannabinoid-based Antitumor Drug Forecasted Market Size by Type (2027-2032)
4 Cannabinoid-based Antitumor Drug Breakdown Data by Application
- 4.1 Global Cannabinoid-based Antitumor Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Cannabinoid-based Antitumor Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Cannabinoid-based Antitumor Drug Market Perspective (2021-2032)
- 5.2 Global Cannabinoid-based Antitumor Drug Growth Trends by Region
- 5.2.1 Global Cannabinoid-based Antitumor Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Cannabinoid-based Antitumor Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Cannabinoid-based Antitumor Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Cannabinoid-based Antitumor Drug Market Dynamics
- 5.3.1 Cannabinoid-based Antitumor Drug Industry Trends
- 5.3.2 Cannabinoid-based Antitumor Drug Market Drivers
- 5.3.3 Cannabinoid-based Antitumor Drug Market Challenges
- 5.3.4 Cannabinoid-based Antitumor Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Cannabinoid-based Antitumor Drug Players by Revenue
- 6.1.1 Global Top Cannabinoid-based Antitumor Drug Players by Revenue (2021-2026)
- 6.1.2 Global Cannabinoid-based Antitumor Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Cannabinoid-based Antitumor Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Cannabinoid-based Antitumor Drug Head Office and Area Served
- 6.4 Global Cannabinoid-based Antitumor Drug Players, Product Type & Application
- 6.5 Global Cannabinoid-based Antitumor Drug Manufacturers Established Date
- 6.6 Global Cannabinoid-based Antitumor Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Cannabinoid-based Antitumor Drug Market Size (2021-2032)
- 7.2 North America Cannabinoid-based Antitumor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Cannabinoid-based Antitumor Drug Market Size by Country (2021-2026)
- 7.4 North America Cannabinoid-based Antitumor Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Cannabinoid-based Antitumor Drug Market Size (2021-2032)
- 8.2 Europe Cannabinoid-based Antitumor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Cannabinoid-based Antitumor Drug Market Size by Country (2021-2026)
- 8.4 Europe Cannabinoid-based Antitumor Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Cannabinoid-based Antitumor Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Cannabinoid-based Antitumor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Cannabinoid-based Antitumor Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Cannabinoid-based Antitumor Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Cannabinoid-based Antitumor Drug Market Size (2021-2032)
- 10.2 South America Cannabinoid-based Antitumor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Cannabinoid-based Antitumor Drug Market Size by Country (2021-2026)
- 10.4 South America Cannabinoid-based Antitumor Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Cannabinoid-based Antitumor Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Cannabinoid-based Antitumor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Cannabinoid-based Antitumor Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Cannabinoid-based Antitumor Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Cannabics Inc.
- 12.1.1 Cannabics Inc. Company Information
- 12.1.2 Cannabics Inc. Business Overview
- 12.1.3 Cannabics Inc. Revenue in Cannabinoid-based Antitumor Drug Business (2021-2026)
- 12.1.4 Cannabics Inc. Cannabinoid-based Antitumor Drug Product Portfolio
- 12.1.5 Cannabics Inc. Recent Developments
- 12.2 GW Pharmaceuticals
- 12.2.1 GW Pharmaceuticals Company Information
- 12.2.2 GW Pharmaceuticals Business Overview
- 12.2.3 GW Pharmaceuticals Revenue in Cannabinoid-based Antitumor Drug Business (2021-2026)
- 12.2.4 GW Pharmaceuticals Cannabinoid-based Antitumor Drug Product Portfolio
- 12.2.5 GW Pharmaceuticals Recent Developments
- 12.3 Jay Pharma
- 12.3.1 Jay Pharma Company Information
- 12.3.2 Jay Pharma Business Overview
- 12.3.3 Jay Pharma Revenue in Cannabinoid-based Antitumor Drug Business (2021-2026)
- 12.3.4 Jay Pharma Cannabinoid-based Antitumor Drug Product Portfolio
- 12.3.5 Jay Pharma Recent Developments
- 12.4 Medicanja Ltd
- 12.4.1 Medicanja Ltd Company Information
- 12.4.2 Medicanja Ltd Business Overview
- 12.4.3 Medicanja Ltd Revenue in Cannabinoid-based Antitumor Drug Business (2021-2026)
- 12.4.4 Medicanja Ltd Cannabinoid-based Antitumor Drug Product Portfolio
- 12.4.5 Medicanja Ltd Recent Developments
- 12.5 Tikun Olam
- 12.5.1 Tikun Olam Company Information
- 12.5.2 Tikun Olam Business Overview
- 12.5.3 Tikun Olam Revenue in Cannabinoid-based Antitumor Drug Business (2021-2026)
- 12.5.4 Tikun Olam Cannabinoid-based Antitumor Drug Product Portfolio
- 12.5.5 Tikun Olam Recent Developments
- 12.6 Valeant Pharmaceuticals
- 12.6.1 Valeant Pharmaceuticals Company Information
- 12.6.2 Valeant Pharmaceuticals Business Overview
- 12.6.3 Valeant Pharmaceuticals Revenue in Cannabinoid-based Antitumor Drug Business (2021-2026)
- 12.6.4 Valeant Pharmaceuticals Cannabinoid-based Antitumor Drug Product Portfolio
- 12.6.5 Valeant Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst